Exactus appoints executive business leader Julian Pittam to board chairman

Exactus Inc (OTCQB:EXDI), a leading supplier of hemp-derived ingredients such as CBD and feminized hemp genetics, announced Monday the appointment of executive business leader Julian Pittam to board chairman. “Julian Pittam has been an investor and a friendly voice of wisdom since our inception, and we are honored to have him join as Chairman of the Board at this pivotal moment,” said Interim CEO Emiliano Aloi in a statement. “Julian brings an impressive track record of over 20 years of extensive experience in investment banking, innovation, and boardroom buildout. His leadership will be vital to the continued development and success of Exactus, including building a Board that both attracts and proactively supports top tier management assets and developing the right committees for integration of new business units as the industry transitions into a massive consolidation phase.” READ: Exactus says strong 2019 sees it building foundation to become an industry leader Exactus said Pittam started his career at Bankers Trust in sales and trading. He spent three years in Hong Kong and Singapore with Bankers Trust before returning to London to work for Lehman Brothers in 1999.  After leaving Lehman in 2005, he became partner and managing director of Data Explorers where he grew the business exponentially in six years until it was sold to Markit.  Pittam then became head of EMEA for ENSO Financial until 2016 when it was sold. Since then he has held non-executive director roles at numerous companies and is an early-stage investor in companies that can demonstrate a great idea but lack finance or business experience. “Exactus has built an impressive leadership team and foundation from which to grow. As a current shareholder of the company, I am pleased to be appointed chairman of the board to help build shareholder value,” Pittam said. Exactus began in 2020 with the goal of being the leader in the hemp industry while developing a strong foundation within the executive team, board of directors and advisory board. The company said it is looking forward to achieving its goal of providing the highest quality specialty cannabinoids, finished products and offering white label services in the second half of the year. Contact the author: patrick@proactiveinvestors.com Follow him on Twitter @PatrickMGraham